Intellia Therapeutics (NTLA) Competitors $12.18 +0.10 (+0.83%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NTLA vs. VKTX, TGTX, BBIO, CRNX, KRYS, ACLX, ADMA, RARE, APLS, and BHVNShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Viking Therapeutics (VKTX), TG Therapeutics (TGTX), BridgeBio Pharma (BBIO), Crinetics Pharmaceuticals (CRNX), Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Intellia Therapeutics vs. Viking Therapeutics TG Therapeutics BridgeBio Pharma Crinetics Pharmaceuticals Krystal Biotech Arcellx ADMA Biologics Ultragenyx Pharmaceutical Apellis Pharmaceuticals Biohaven Viking Therapeutics (NASDAQ:VKTX) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation. Do institutionals & insiders have more ownership in VKTX or NTLA? 76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 4.7% of Viking Therapeutics shares are held by company insiders. Comparatively, 3.2% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, VKTX or NTLA? Viking Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Do analysts recommend VKTX or NTLA? Viking Therapeutics currently has a consensus price target of $106.75, suggesting a potential upside of 152.66%. Intellia Therapeutics has a consensus price target of $54.94, suggesting a potential upside of 351.05%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Viking Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.15Intellia Therapeutics 0 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.72 Is VKTX or NTLA more profitable? Viking Therapeutics' return on equity of -12.73% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -12.73% -12.31% Intellia Therapeutics N/A -49.34%-40.27% Does the MarketBeat Community prefer VKTX or NTLA? Viking Therapeutics received 184 more outperform votes than Intellia Therapeutics when rated by MarketBeat users. Likewise, 79.87% of users gave Viking Therapeutics an outperform vote while only 69.27% of users gave Intellia Therapeutics an outperform vote. CompanyUnderperformOutperformViking TherapeuticsOutperform Votes61979.87% Underperform Votes15620.13% Intellia TherapeuticsOutperform Votes43569.27% Underperform Votes19330.73% Which has stronger valuation & earnings, VKTX or NTLA? Viking Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$85.89M-$0.93-45.43Intellia Therapeutics$43.09M28.79-$481.19M-$5.44-2.24 Does the media refer more to VKTX or NTLA? In the previous week, Viking Therapeutics had 17 more articles in the media than Intellia Therapeutics. MarketBeat recorded 22 mentions for Viking Therapeutics and 5 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.64 beat Viking Therapeutics' score of 0.47 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 7 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive SummaryViking Therapeutics beats Intellia Therapeutics on 10 of the 16 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.24B$2.51B$5.02B$9.08BDividend YieldN/A0.73%4.87%4.18%P/E Ratio-2.246.07135.2017.17Price / Sales28.7975.031,120.31115.67Price / CashN/A15.0540.5837.88Price / Book1.043.284.754.78Net Income-$481.19M$29.98M$118.50M$225.60M7 Day Performance-5.58%-1.24%-1.83%-1.26%1 Month Performance-7.16%10.59%12.27%4.37%1 Year Performance-58.88%-22.23%31.72%18.73% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.1186 of 5 stars$12.18+0.8%$54.94+351.0%-58.9%$1.24B$43.09M-2.24600High Trading VolumeVKTXViking Therapeutics4.2908 of 5 stars$48.35+2.8%$106.75+120.8%+139.8%$5.39BN/A-51.5620Analyst ForecastGap UpTGTXTG Therapeutics4.3117 of 5 stars$34.42+7.5%$40.67+18.1%+87.1%$5.36B$233.66M-320.17290Positive NewsBBIOBridgeBio Pharma4.6924 of 5 stars$28.07+2.1%$47.69+69.9%-30.7%$5.30B$217.77M-11.63400Positive NewsCRNXCrinetics Pharmaceuticals4.0687 of 5 stars$54.22+1.0%$70.82+30.6%+55.4%$5.03B$1.04M-14.39210Positive NewsKRYSKrystal Biotech4.5152 of 5 stars$171.83+5.0%$206.67+20.3%+45.9%$4.94B$50.70M92.45229Analyst ForecastACLXArcellx3.1314 of 5 stars$85.01+1.4%$105.93+24.6%+49.1%$4.60B$155.82M-118.03130Positive NewsADMAADMA Biologics3.7647 of 5 stars$19.13+2.9%$21.25+11.1%+325.4%$4.52B$382.81M68.32530Positive NewsGap DownRAREUltragenyx Pharmaceutical4.4437 of 5 stars$46.25+1.0%$87.46+89.1%-2.6%$4.27B$434.25M-7.081,276Analyst ForecastNews CoverageAPLSApellis Pharmaceuticals4.5591 of 5 stars$33.34+0.5%$49.94+49.8%-39.6%$4.15B$396.59M-16.35702Analyst DowngradePositive NewsBHVNBiohaven3.7123 of 5 stars$40.25+4.6%$63.00+56.5%-4.4%$4.07B$462.51M-4.11239Analyst Forecast Related Companies and Tools Related Companies Viking Therapeutics Alternatives TG Therapeutics Alternatives BridgeBio Pharma Alternatives Crinetics Pharmaceuticals Alternatives Krystal Biotech Alternatives Arcellx Alternatives ADMA Biologics Alternatives Ultragenyx Pharmaceutical Alternatives Apellis Pharmaceuticals Alternatives Biohaven Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NTLA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NTLA Stock Alerts